We report here that a bacterial protease inhibitor from Brucella spp. called U-Omp19 behaves as an ideal constituent for a vaccine formulation against infectious diseases. When co-administered orally with an antigen (Ag), U-Omp19: i) can bypass the harsh environment of the gastrointestinal tract by inhibiting stomach and intestine proteases and consequently increases the half-life of the co-administered Ag at immune inductive sites: Peyer's patches and mesenteric lymph nodes while ii) it induces the recruitment and activation of antigen presenting cells (APCs) and increases the amount of intracellular Ag inside APCs. Therefore, mucosal as well as systemic Ag-specific immune responses, antibodies, Th1, Th17 and CD8 + T cells are enhanced when U-Omp19 is co-administered with the Ag orally. Finally, this bacterial protease inhibitor in an oral vaccine formulation confers mucosal protection and reduces parasite loads after oral challenge with virulent Toxoplasma gondii.
Among different mucosal routes, oral delivery is the natural choice not only for drugs, but also for vaccines, by virtue of its ease of administration and cost. Although oral delivery of vaccines has been the Holy Grail for generations of vaccinologists [1] , oral vaccination has been historically thought to be largely ineffective at providing effective mucosal and/or systemic immunity. This is mainly due to the fact that antigens (Ags) undergo proteolytic degradation in the stomach and intestine. Another barrier that would be bypassed by inducing an appropriate inflammatory response is the immune tolerance resulting from Ag feeding [2] . Consequently, to reliably immunize orally with peptide-or protein-based vaccines, Ags must be protected, uptake enhanced and the immune tolerance properly controlled.
Induction of immune responses following mucosal immunization with non-live vaccines is usually dependent upon the coadministration of appropriate adjuvants that can initiate and support the transition from innate to adaptive immunity [3] . Currently, to induce mucosal adaptive immune responses -in mice -two powerful adjuvants are used: cholera toxin (CT) from Vibrio cholera and labile enterotoxin (LT) from Escherichia coli [4] . In humans, however, they are responsible for the cholera and "Travelers diarrhea" and therefore cannot be used. In attempt to avoid the enterotoxic effects caused mainly by the A subunit of the cholera toxin, subunit B (CTB) was expressed and is now being used in a human vaccine (Dukoral®) [5] . Doublemutant LT (dmLT), with reduced enterotoxicity was developed and shown to increase immune responses [6] . Different strategies to increase Ag delivery like antigen targeting to M cells, nanoparticle-releasing vaccines at the colon, etc. for enhancing the efficacy of mucosal vaccines have been and are currently being investigated [7] [8] [9] [10] . Meanwhile different new approaches need to be explored to develop novel oral adjuvants and delivery systems [11] , especially there is a need of those that can induce T helper (Th)1 and CD8 + T cell responses that can prevent infectious diseases related to intracellular pathogens. In our laboratory we have been working on the use of a Brucella spp. protein devoid of its lipid moiety called U-Omp19 (Unlipidated Outer membrane protein 19) as an antigen for a vaccine against brucellosis. This protein is soluble and easy to express and purify at high scales [12, 13] . Oral immunization with U-Omp19 produced either in E. coli or in plants without adjuvants conferred significant protection against oral B. abortus infection and induced a mixed Th1-17 immune response independent of TLR4. U-Omp19 also induced the maturation of murine dendritic cells (DCs) in vivo [14] .
Of note, BLAST, Pfam and MEROPS sequence analysis report that U-Omp19 has sequence identity with other bacterial protease inhibitors, particularly with those of the protease inhibitor family inh from Erwinia chrysanthemi (family I38) [15, 16] . This family of proteins would interact with specific proteases released by plant, insect and animal pathogens [15, 17] . Thus, we hypothesize that U-Omp19 would inhibit protease activity at mucosal tissues and would increase the half-life of the co-administered Ag thus increasing its immunogenicity.
In this work we demonstrate that this bacterial protease inhibitor protects antigens delivered in oral vaccines from digestion while triggers specific mucosal immune responses. To our knowledge there are no reports in the literature describing the use of bacterial protease inhibitors in oral vaccine formulations. Therefore, this is an unconventional bacterial molecular pattern never explored before.
Materials and methods

Ethics statement
All experimental protocols of this study were conducted in strict accordance with international ethical standards for animal experimentation (Helsinki Declaration and its amendments, Amsterdam Protocol of welfare and animal protection and National Institutes of Health, USA NIH, guidelines: Guide for the Care and Use of Laboratory Animals). The protocols of this study were approved by the Institutional Committee for the Care and Use of Laboratory Animals (CICUAL) from the University of Buenos Aires (Permit Number: 2079) and CICUAE from University of San Martin (Permit Number: 052,014), Buenos Aires, Argentina.
Animals
Eight week old female BALB/c, C57BL/6 or C3H/HeN mice were purchased from University of La Plata (La Plata, Argentina) or from University of San Martín (UNSAM) and housed in the animal resources facility of University of Buenos Aires (UBA) or UNSAM (Buenos Aires, Argentina). Animals were devoid of food but with free access to water 2 h previous and 2 h after any administration/immunization.
Ags and adjuvants
Chicken egg OVA grade V (Sigma) was used as a model Ag. Recombinant unlipidated (U)-Omp19 was obtained as previously described [13] . LPS contamination from U-Omp19 was adsorbed with Sepharosepolymyxin B (Sigma). Endotoxin determination was performed with Limulus amoebocyte chromogenic assay (LONZA). All U-Omp19 preparations used contained b0.1 endotoxin units per mg of protein. CT and aprotinin were purchased from Sigma.
Determination of protease inhibitor activity in vitro and in vivo
Protease activity was determined using a casein fluorimetric kit (EnzChek, Invitrogen). This kit has casein-BODIPY-FL, whose fluorescence is quenched. Protease-catalyzed hydrolysis relieves this quenching, yielding bright green fluorescent peptides. The increase in fluorescence emission is proportional to casein digestion and protease activity. Pepsin (0.483 μM, Sigma), pancreatic Elastase (0.965 μM, Sigma), Trypsin (0.965 μM, Sigma), α-Chymotrypsin (0.965 μM, Sigma), Carboxypeptidase A (0.160 μM, Sigma) and B (0.065 μM, Sigma) were incubated with U-Omp19 at different molar ratios protease:U-Omp19 (1:1, 1:5, 1:10 and 1:50 -only for pepsin). As positive control a mammalian protease inhibitor cocktail was used. Bovine serum albumin (BSA) and U-Omp16 -a Brucella spp. protein with a similar molecular weight to U-Omp19 and expressed and purified in the same way -were used as negative controls. Each reaction mix was incubated at room temperature (RT) for 1 h and then substrate (casein-BODIPY-FL, 1 μg/ml) was added. Fluorescence was measured with a fluorescence plate reader (FilterMaxF5 Molecular devices).
To study pH stability of the inhibitory activity of U-Omp19, UOmp19 was pre-incubated at RT for 1 h at different pH (2, 5, 7.5 and 8) buffers containing 10 mM sodium phosphate and 50 mM NaCl and then adjusted to the optimum pH for α-Chymotrypsin (pH = 7.8). Microcon 3 (Biopore, Germany) was then used to exchange buffers. Residual inhibitor activity was assessed using casein-BODIPY (1 μg/ml) and α-chymotrypsin (0.965 μM) as model protease in a molar ratio protease: U-Omp19 of 1:10. Thermal stability of the inhibitory activity of U-Omp19 was assessed by incubating different tubes containing U-Omp19 at different temperatures (25-100°C) for 1 h and subsequently adjusting them at RT. Residual inhibitor activity was assessed as above described for pH stability experiments using casein-BODIPY-FL and α-chymotrypsin or elastase (0.965 μM) as model proteases. Far-UV circular dichroism (CD) spectra of U-Omp19 under different pHs and temperatures were conducted (see supp. Materials and methods).
To further study the protease inhibitory mechanism of U-Omp19, the kinetic of trypsin, α-chymotrypsin and pancreatic elastase inhibition was performed (see supp. Materials and methods).
To evaluate if U-Omp19 inhibits proteolytic activity of stomach and intestine extracts, stomach or intestine extracts from mice were preincubated with buffer, different amounts of U-Omp19, Inhibitor cocktail or BSA as negative control. Then, the mixtures were incubated with casein BODIPY-FL for 1 h or with OVADQ (quenched protein that releases fluorescence upon digestion) for 4 h and the fluorescence increment was determined.
To study protease inhibitor activity in vivo BALB/c mice were orallyintragastrically (i.g.) -administered with casein-BODIPY alone (100 μg), plus U-Omp19 (150 μg) or aprotinin (1 μg). Stomachs were removed 15 min and 1 h after oral delivery and extracts of the organs were obtained. Afterwards Ag digestion was determined by fluorescence emission. The dose of aprotinin used in this work was chosen because it did not produce adverse effects on treated animals and also induced proteolysis inhibition of the antigen similar to U-Omp19 (data presented in this manuscript and not shown).
To study Ag fate after delivery BALB/c mice were i.g. administered with PBS, OVA-FITC (100 μg) alone or OVAFITC (100 μg) plus UOmp19 (150 μg). Stomachs and small intestines were removed 90 min after oral delivery and extracts of the organs were obtained. Afterwards Ag presence was determined by fluorescence emission.
Determination of Ag fate and proteolysis in vivo
To study Ag proteolysis in vivo Casein-BODIPY-FL or OVADQ were used. To evaluate Ag fate and internalization in vivo OVAAlexaFluor647 or OVA-FITC were used. If Ags (OVA-FITC or casein-BODIPY-FL) were used alone, mice were fed Ag (100 μg) plus i) buffer, ii) U-Omp19 (150 μg), iii) CT (10 μg), iv) aprotinin (1 μg) or buffer as control. To examine simultaneously Ag fate and degradation, mice were fed both Ags simultaneously (100 μg OVA-AlexaFluor647 and 100 μg OVADQ) plus i) buffer, ii) U-Omp19 (300 μg), iii) CT (20 μg), iv) aprotinin (2 μg) or buffer as control. At 2, 6, 12 and 18 h post administration mice were sacrificed and Peyer's Patches (PPs) and Mesenteric Lymph Nodes (MLNs) were aseptically removed. Single cell suspensions were prepared [18] , and washed twice in PBS solution to eliminate any extracellular Ag, thus the fluorescence determination was proportional to Ag presence or proteolysis inside the cells. Total viable cells were counted using Trypan Blue. Fluorescence intensity (FI) in arbitrary units was determined in 1 × 10 6 cells. % of max. internalization of OVA or % of OVA degradation was calculated as described in supplemental material and methods.
To study cell subtypes involved in Ag internalization and processing, cells were stained with fluorochrome conjugated antibodies: antiCD11c, anti-CD8α, anti-CD11b and anti-MHC-II or isotype controls and analyzed by flow cytometry using FACSAriaII and FlowJo software (Tree Star, OR).
Immunizations
BALB/c mice were orally immunized as described for other adjuvants [19, 20] on days 1, 2, 3, 8, 9 and 10 with OVA (100 μg), OVA + U-Omp19 (150 μg), OVA + CT (10 μg) or OVA + aprotinin (1 μg). C57BL/6 mice were immunized on days 0, 7 and 14. One month after the last immunization mice were sacrificed to study immune responses.
Determination of T helper immune responses
Spleen, PPs and MLNs single cell suspensions from immunized mice were cultured in duplicates at 4 × 10 6 cells/ml in RPMI 1640
supplemented with 10% FCS (Life Technologies), sodium pyruvate (1 mM), L-glutamine (2 mM), penicillin 100 U/ml, and streptomycin (100 mg/ml) (complete medium) and stimulated with OVA, or complete medium alone. After 72 h or 5 days of incubation at 37°C in a humidified atmosphere (5% CO 2 ) cell culture supernatants were collected. IFN-γ, IL-4, IL-10 and IL-17 were determined by ELISA (Pharmingen and R&D systems).
Intracellular IFN-γ determination
Splenocytes from immunized mice were cultured (4 × 10 6 cells/well) in presence of complete medium (supplemented with IL-2) or Ag stimuli (IL-2 plus OVA -500 μg/ml, A20JOVA mitomicyn-treated cells as a source of APCs (25:1) and OVA 323 peptide) for 18 h. Next, brefeldin A was added for 5 h more to the samples. After that, cells were treated and analyzed as described previously [13] .
Determination of Ab responses
BALB/c mice were orally immunized as described on days 1, 2, 3, 8, 9 and 10 with CT (10 μg) or CT + U-Omp19 (10 + 150 μg). Same immunization schedule was used when Shiga toxin (ST) was selected as Ag. Other groups of mice were orally immunized with heat killed extract from Salmonella-HKS (60 μg) or HKS + U-Omp19 (60 + 150 μg) on days 0, 7 and 14. Feces and sera were obtained as described previously [21] 2 weeks after last immunization to study Ag-specific-or UOmp19-specific IgA or IgG responses. Cut-off values for the ELISA assays were calculated as the mean specific OD plus 3 SD from 20 sera or feces from non-immunized mice. Sera or feces titers were established as the reciprocal of the last dilution yielding an OD higher than the cut-off.
Pathogen challenge assays
C3H/HeN mice were orally immunized on days 1, 2, 3, 8, 9 and 10 with PBS, purified recombinant E. coli GRA4 (30 μg), GRA4 + UOmp19 (100 μg) or GRA4 + CT (10 μg). Two weeks after the last immunization, some mice per group were injected intradermally in one footpad with 20 μg of Ag (GRA4) and in the contralateral footpad with an equal volume of saline. Footpad thickness was measured 72 h later using a digital caliper with a precision of 0.01 mm, and the mean increase in footpad thickness (mm) was calculated as: (footpad thickness) Ag − (footpad thickness) saline. Three weeks after last immunization other mice were orally infected with 20 T. gondii tissue cysts of the ME49 strain. Serum samples were obtained 8 days post challenge and the activity of aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and alanine aminotransferase (ALT) were measured as an indication of liver damage [22] (Wiener Lab., Argentina). One month after challenge, mice were sacrificed and their brains removed and homogenized to determine the mean number of cysts per brain by observation under optical microscope as described [23] .
Statistical analysis
Statistical analysis and plotting were performed using GraphPad Prism 4 software (GraphPad, San Diego, CA). In experiments with more than 2 groups, data were analyzed using one-way ANOVA with Bonferroni's post-test. If necessary, a logarithmic transformation was applied prior to the analysis to obtain data with a normal distribution. In experiments with 2 groups, Unpaired T Test was used. A P value less than 0.05 was considered significant. When bars are plotted results are expressed as mean ± SEM for each group.
Results
The protein moiety of B. abortus Omp19 (U-Omp19) is a protease inhibitor
BLAST, Pfam and MEROPS sequence analysis report that U-Omp19 has significant sequence identity with other bacterial protease inhibitors, particularly with those representatives of inh protease inhibitor family (family I38, clan IK): Pseudomonas aeruginosa protease inhibitor (APRin), Serratia marcescens protease inhibitor and E. chrysanthemi protease inhibitor (Inh) [15, 16] (Fig. 1A and supp. Materials and methods). Superposition of the known three-dimensional structures of Inh or APRin with the homology model of Brucella U-Omp19 (obtained with the SWISS MODEL server [24] ) were performed. U-Omp19's beta barrel core is predicted to be structurally similar to Inh and APRin (Fig. 1B) .
Then, the ability of U-Omp19 to inhibit gastrointestinal proteases was studied for the first time. U-Omp19 is a protease inhibitor since it was able to inhibit in vitro the activity of proteases present in the stomach (pepsin, P b 0.001) and proteases secreted from the pancreas to the intestine (elastase, trypsin and α-chymotrypsin, P b 0.001). Also it partially inhibited the activity of carboxypeptidase B (P b 0.01) but could not inhibit carboxypeptidase A (Fig. 1C) . Bovine Serum Albumin (BSA) and U-Omp16 from Brucella (a Brucella Omp with a molecular weight very similar to U-Omp19) did not inhibit the enzymatic activity of any of the proteases tested when used in a similar molar ratio to UOmp19, further indicating the specificity of the reaction assayed (Fig. 1C) .
These assays were performed under the optimal pHs of each protease. Of note, U-Omp19 inhibited in vitro pepsin activity at pH 2 suggesting that its structure is stable at this low pH present at the stomach. To confirm this, Far-UV circular dichroism (CD) spectra of U-Omp19 under different pHs and temperatures were conducted, which indicated that U-Omp19 did not suffer any evident structural change under pH 2, 5 or 7.5. A control performed with U-Omp19 in a buffer containing 6 M guanidinium chloride showed the loss of CD signal between 210 and 240 nm expected for a denatured U-Omp19. Moreover, the thermal denaturation experiment showed no significant denaturation as CD signal between 210 and 235 nm was still present after heating U-Omp19 to 90°C (Fig. 1D-E) . Consequently U-Omp19 retained its full protease inhibitor activity when previously exposed to a broad pH (2) (3) (4) (5) (6) (7) (8) or temperature (25-100°C) range (P b 0.001) (Fig. 1F-G) .
To further study the protease inhibitory mechanism of U-Omp19, the kinetic of trypsin ( Fig. 2A) , α-chymotrypsin (Fig. 2B ) and pancreatic elastase (Fig. 2C ) inhibition was studied (see Supp. Materials and methods). Lineweaver-Burk and Dixon plots indicated that U-Omp19 inhibited the three serine proteases in a mixed noncompetitive manner [25] (Fig. 2 left and middle panels) , indicating that U-Omp19 binds both, the free proteases and the protease-substrate binary complexes. As UOmp19 does not compete with the substrates for binding to the free proteases; it binds these serine proteases at a site distinct from the active site. Global nonlinear fit of data was used to estimate K i and alpha values. Determined K i values (Mean; Std Error) were: (77.39 μM; 21.23) for Trypsin, (55.75 μM; 10.40) for α-Chymotrypsin and (128.0 μM; 41.6) for pancreatic Elastase. For the three proteases the estimated values of alpha were between 1.8 and 3.4, indicating that UOmp19 bound both, the free proteases and the protease-substrate binary complexes, but with different affinities (Fig. 2, right panels) . Together these results indicate that U-Omp19 exhibits a mixed noncompetitive type inhibitory activity against main gut proteases (trypsin, α-chymotrypsin and elastase) with K i values in the μM range.
As the in vivo content and proportion of proteases in the gastrointestinal tract is diverse in the different organs, the ability of U-Omp19 to inhibit proteases activity in stomach or intestine extracts was studied. UOmp19 was able to partially (40-60%) inhibit in vitro the protease activity of stomach (P b 0.001) or intestine (P b 0.001) extracts from mice using two different substrates: casein and ovalbumin (OVA) (Fig. 3A-B) . As expected, BSA did not inhibit the proteolytic activity of stomach or intestine extracts in vitro whereas a protease inhibitor cocktail did (Fig. 3A-B) .
To study in vivo the biological activity of U-Omp19 animals were i.g. administered, on one occasion, with casein-BODIPY (model Ag which exposes its dyes and fluoresces when digested) alone, plus U-Omp19 or plus aprotinin. Stomachs were removed 15 min and 1 h (h) later and casein digestion was determined. Oral co-administration of UOmp19 prevented Ag degradation in vivo (~50%) in the stomach (P b 0.001) of mice at 15 min (Fig. 3C) . The proteolysis inhibition was a slight lesser than that obtained when aprotinin was used. At 60 min there is still significant reduction (P b 0.05) in Ag digestion (~25%) at the stomach (Fig. 3C) . Moreover, using OVA-FITC as a model Ag in vivo there was an increase, at 90 min post-delivery, in the amount of Ag at the stomach (slight but not significant) and intestine (P b 0.05) when it was coadministered orally with U-Omp19 (Fig. 3D) .
Taken together these and above results indicate that U-Omp19 is a pH-and temperature-resistant, protease inhibitor of stomach and gut proteases. Digestive enzymes break down large polypeptides into nonimmunogenic di-and tri-peptides, too small to bind to major histocompatibility complex (MHC) molecules [26] . Accordingly with the inhibition of the stomach and gut proteases, U- 0.01 at 18 h post delivery) (Fig. S3) . CT co-administration or aprotinin induced lower monocyte-and DC-recruitment (Fig. S3) . Moreover, only U-Omp19 was able to induce the recruitment of a particular DC subtype: CD11c + CD8α + DCs, known to stimulate Th1 responses and Ag crosspresentation to CD8 + T cells [27] (Fig. S3 ).
Oral U-
Worth mentioning, U-Omp19 co-administered by the oral route increased the amount of Ag within monocytes and CD11c + CD8α + DCs at PPs and MLNs (Fig. 4C) . In agreement to the results shown in Figs. 1-3 , the amount of digested Ag inside monocytes and CD11c + CD8α + DCs from PPs partially decreased after oral U-Omp19 co-administration (Fig. S4) . Furthermore, U-Omp19 oral administration induced in vivo 
(C) U-
Omp19 is a protease inhibitor. Protease inhibitor activity was determined using casein BODIPY-FL assay kit in which the increment in fluorescence is proportional to proteolytic activity. Pepsin, elastase, trypsin, α-chymotrypsin, carboxypeptidase A and B were pre-incubated in the optimal buffer for each enzyme for 1 h at different molar ratios with U-Omp19 (enzyme:UOmp19 -1:1, 1:5, 1:10 and 1:50 only with pepsin) or without U-Omp19 (1:0). A mammalian protease inhibitor cocktail was used as positive control and BSA and U-Omp16 as negative controls at 1:10 M ratio. Then, were incubated with 1 μg/ml casein BODIPY-FL for 1 h. Inhibitor activity is expressed as percentage of protease activity remaining when compared to condition 1:0. These results indicate that U-Omp19 induces the recruitment and activation of APCs to mucosal inductive sites and can increase Ag intracellular half-life in APCs.
Oral co-administration of U-Omp19 increases mucosal and systemic T lymphocyte adaptive immune responses
To study if oral delivery of OVA in the presence of U-Omp19 resulted in a significantly increased adaptive immune response, BALB/c mice were orally immunized with OVA plus i) buffer, ii) U-Omp19, iii) CT or iv) aprotinin. MLNs cells from OVA + U-Omp19 immunized mice produced significant amounts of IFN-γ and IL-17 in response to OVA (P b 0.05 vs OVA immunized mice, Fig. 5A ). On the contrary, the same cells did not produce IL-4 or IL-10 after OVA in vitro stimulation (data not shown). Also, co-administration of OVA plus U-Omp19 induced OVA-specific IFN-γ at the spleens (P b 0.05). A slight but not statistically significant OVA-specific IL-17 production was evidenced only in the spleens of OVA + U-Omp19 immunized animals (Fig. 5A) . OVAspecific IFN-γ producing CD4
+ and CD8 + T cells were found in animals immunized with OVA plus U-Omp19 (Fig. 5B) . In contrast, CT or aprotinin co-administration did not induce OVA-specific IFN-γ producing CD4 + T or CD8 + T cells nor IFN-γ or IL-17 secretion from stimulated MLNs and splenocytes (Fig. 5A-B) . Similarly, animals immunized with OVA + U-Omp19 showed OVA-specific T cell responses in vivo (DTH assay) (P b 0.05) while animals immunized with OVA or OVA + CT did not (Fig. S5A) . Also, oral co-administration of U-Omp19 or aprotinin induced a slight but not significant increase in anti-OVA IgA in feces, while CT + OVA did it (P b 0.05) (Fig. S5B) . Important, anti-U-Omp19 IgA or anti-U-Omp19 IgG was not detected in any immunized group (Fig. S5B-C) . U-Omp19 immunization alone did not elicit specific adaptive immune responses to OVA (Figs. S5A and S9 ). The α4β7 integrin is critical for lymphocyte homing to the small intestine [28] . Oral delivery of OVA with U-Omp19 resulted in a significantly increased population of MLN CD4 + and CD8 + T cells with upregulated α4β7 integrin expression 1 month after immunization in BALB/c mice. A similar degree of up-regulation was observed when OVA was co-administered with CT (Fig. S5D) .
To study adaptive immune responses under a different genetic background, C57BL/6 mice were orally immunized with OVA, OVA + U-Omp19 or OVA + CT. One month later, OVA specific-Th1 and OVA-specific IFN-γ producing CD4 + T and CD8 + T cells were evidenced at the mucosal as well as systemic level, if U-Omp19 was co- administered orally with OVA (P b 0.01 vs OVA immunized mice) (Fig. S6) . These results indicate that U-Omp19 has a similar immune adjuvant effect in BALB/c and C57BL/6 mice.
Together these results indicate that oral co-administration of this bacterial protease inhibitor with Ag increases mucosal and systemic Ag-specific Th1, Th17 and CD8 + T cell immune responses.
U-Omp19 co-administered orally with bacterial Ags increases Agspecific mucosal IgA and systemic IgG responses
OVA-specific antibody (Ab) mucosal responses were difficult to achieve using U-Omp19 (Fig. S5B-C) . Thus, to test U-Omp19's capacity to elicit Ab responses we decided to use other Ags, such as Shiga Toxin (Stx2) from E. coli, CT from Vibrio cholera or a heat killed extract from Salmonella typhimurium (HKS). There was a significant increase (P b 0.01) in anti-ST IgA in feces when ST was orally co-administered with U-Omp19 (Fig. 6A and supplementary material and methods) . Serum anti-ST IgG responses were not induced in any immunized group (Fig. S7A) . Oral co-administration of U-Omp19 with CT (as Ag) induced increased (P b 0.05 vs CT alone) anti-CT IgA in feces and IgG in sera (Fig. 6B) . Also, U-Omp19 oral co-administration with HKS increased anti-HKS fecal IgA and serum IgG compared with oral delivery of HKS alone (Fig. 6C) . Anti-U-Omp19 serum IgG or fecal IgA were not detected in any immunized group (Fig. S7B-C) .
Altogether these results indicate that U-Omp19 co-administered orally with pathogen-derived Ags can increase Ag-specific mucosal IgA and systemic IgG responses.
U-Omp19 in an oral vaccine formulation induces protection against oral challenge with a virulent parasite
Besides and considering that Toxoplasma gondii is able to infect the host through the gut mucosa and Th1 responses are known to be important in protection [29] , these prompted us to study T. gondii infection model for vaccination using U-Omp19. Thus, the efficacy of oral immunization with a recombinant protein GRA4 plus U-Omp19 was evaluated. C3H/HeN mice were orally immunized with i) PBS, ii) GRA4, iii) GRA4 + U-Omp19 or iv) GRA4 + CT. Three weeks after the last boost, mice were challenged orally with Me49 tissue cysts and individual parasite levels were assessed 1 month later. An important decrease in the brain cyst burden (P b 0.05) together with a reduction in serum of liver damage associated enzymes (AST, LDH and ALT) and an increase (P b 0.05) in GRA4-specific IgA and DTH was observed in GRA4 + UOmp19 immunized mice as compared to the control groups (Fig. 7A-C) . These results together indicate that U-Omp19 could be a useful constituent of oral vaccine formulations against infectious diseases.
Conclusions and discussion
There is no vaccine that is more amenable to mass immunization in field settings than oral vaccine. Yet, there is a relative paucity of oral vaccines in current medical practice. The greatest threat to peptide and protein oral administration lies in the small intestine, which contains large quantities of peptidases. For example, luminal digestion in the duodenum by trypsin and chymotrypsin can convert almost half of the ingested protein to trichloroacetic acid-soluble material within 10 min, 60-70% of which is in the form of small peptides with 2-6 amino acids that cannot bind MHC molecules [26] .
As demonstrated in this work, we have completed proof of concept studies that indicate that a Brucella spp. protein would be a useful component in an oral vaccine formulation because: i) it bypasses the hostile environment of the gastrointestinal tract inhibiting stomach and gut proteases and consequently increases the half-life of co-administered Ags at the inductive sites: PPs and MLNs while ii) it induces the recruitment of APCs, activation and Ag internalization. Besides, it reduces the amount of digested Ag within APCs at inductive sites. Consequently, mucosal as well as systemic Ag-specific immune responses, Abs, Th1, Th17 and CD8 + T cells are enhanced if U-Omp19 is orally coadministered with the Ag. The inhibition of proteolysis and induction of immune responses has also been demonstrated using BALB/c, C57BL/6 ( Fig. S6 and Supplementary material) or C3H/HeN mice further indicating that U-Omp19 can be used under different genetic backgrounds. Moreover, in this work UOmp19's usefulness was evaluated using model Ags such us OVA and casein as well as bacterial and parasite derived Ags.
As U-Omp19 possesses the capability of partially inhibiting the destruction of the Ag, less Ag would be needed to induce protection, which could lower vaccine costs. Interestingly, this protease inhibitor is pH and thermally stable; these are important attributes that will allow it to work at the low pH from the stomach and its use in vaccines avoiding cold chain. We believe that if U-Omp19 would not be pH stable nor be able to inhibit stomach and gut proteases immune properties can never been seen. This would explain why at present most mucosal adjuvants are given intranasal and not oral to avoid their digestion before reaching immune cells.
Being U-Omp19 a protein, the observed effect on gastrointestinal proteases should be short term and reversible because U-Omp19 -when present in the gut-will be finally digested by the proteases newly secreted from the pancreas to the intestine. In fact, we have demonstrated that U-Omp19 effect on in vivo inhibition of proteolysis is transient. Moreover, the amount of in vivo inhibition is not total, allowing digestion, which would lower the chances of potential adverse effects of U-Omp19 in vaccine formulations. Of note, there were no visible adverse effects in mice or histopathological changes in PPs, MLNs and intestines from U-Omp19 orally immunized mice (Fig. S8) . Worth mentioning, antibody responses against U-Omp19 were not detected in any immunized group. This was reported in our previous work using U-Omp19 alone as Ag [14] and in the present work where UOmp19 was orally co-administered with the Ag. This is of great importance because it was described for other adjuvants and delivery systems that antibody responses against their self may inhibit subsequent utility. Hence these results would support repeated use of U-Omp19 contained in different vaccine formulations without anticipating this problem.
In this work U-Omp19's mechanism of action in vitro on main gut proteases was characterized for the first time and results indicated that U-Omp19 inhibits trypsin, chymotripsin and pancreatic elastase by a mixed non-competitive mechanism of inhibition and with a K i in the μM range. Representative proteins belonging to inh protease inhibitor family as is U-Omp19 from Brucella spp. are: P. aeruginosa Alkaline protease inhibitor (APRin), S. marcescens protease inhibitor (SmaPI) and E. chrysanthemi protease inhibitor (Inh). It is probable that these inhibitors protect bacteria from proteolysis during export of self proteases [30] . Until present there are few studies on these types of protease inhibitors (family inh I38), and all of them were shown to inhibit their cognate -self -or heterologous bacterial proteases [15, 30] . However, while belonging to other family of protease inhibitors there is a known broad spectrum protease inhibitor from bacteria -from the entomopathogenic bacterium Photorhabdus luminescens -that can inhibit also mammalian proteases like trypsin and elastase [17] as is the case for U-Omp19 from Brucella spp. Despite we have demonstrated that U-Omp19 is able to inhibit in vitro protease activity of intestine extracts from large animals like pigs (Fig. S10) we believe that new systems including micro-, nanoparticles and enteric capsules may have significant potential to increase U-Omp19 capacity to work in larger animals using advanced combined formulations in the future.
Although there are studies that postulate the usefulness of mammalian protease inhibitors like aprotinin for the co-administration of oral drugs [31, 32] and before oral immunization [33] to our knowledge there are no published reports describing the use of a bacterial protease inhibitor in oral vaccine formulations. Until present most studies on the immunomodulatory properties of protease inhibitors were conducted on eukaryotic protease inhibitors [34] [35] [36] and some viral as well as filarial nematodes protease inhibitors [35, 37] that were found to be immunoregulatory and anti-inflammatory. For example, a serine leucocyte proteinase inhibitor targets monocytes, which in turn inhibit CD4 + T cell proliferation and Th1 cytokine secretion [36, 38] . In fact, our results demonstrated that a eukaryotic protease inhibitor like aprotinin can limit gastrointestinal digestion of the co-administered Ag but cannot increase immune responses, this last particularity is important for its application on oral delivery of drugs where immune reactions must be avoided. In contrast, a bacterial protease inhibitor inhibits digestion and increases mucosal and systemic Abs, Th1, Th17 and CD8 + immune responses.
The natural route of infection and the need for a Th1-biased response [29] make T. gondii strong candidate for oral vaccination with the novel adjuvant U-Omp19. Consequently, in this work we confirmed U-Omp19's usefulness in an oral subunit vaccine formulation against oral T. gondii infection. Nowadays, most used and approved adjuvants are associated with the induction of Th2 and humoral responses [39] . As U-Omp19 induces Abs, Th1, Th17 and CD8 + T cell mucosal immune responses, the discovery of this novel type of molecules: protease inhibitor/adjuvant lays the groundwork for new directions in mucosal vaccine design against infectious diseases [3, 40] .
